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Background: Approximately 425 million people globally have diabetes, with ~ 90% of these having Type 2
Diabetes Mellitus (T2DM). This is a condition that leads to a poor quality of life and increased risk of serious health
complications. Structured self-management education (SSME) has been shown to be effective in improving
glycaemic control and patient related outcome measures and to be cost-effective. However, despite the
demonstrated benefits, attendance at SSME remains low. An intervention has been developed to embed SSME
called the ‘Embedding Package’. The intervention aims to address barriers and enhance enablers to uptake of SSME
at patient, healthcare professional and organisational levels. It comprises a marketing strategy, user friendly and
effective referral pathways, new roles to champion SSME and a toolkit of resources.
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Methods: A mixed methods study incorporating a wait-list cluster randomised trial and ethnographic study,
including 66 UK general practices, will be conducted with two intervention start times (at 0 and 9 months), each
followed by an active delivery phase. At 18 months, the intervention will cease to be actively delivered and a 12
month observational follow-up phase will begin. The intervention, the Embedding Package, aims to increase SSME
uptake and subsequent improvements in health outcomes, through a clear marketing strategy, user friendly and
effective referral pathways, a local clinical champion and an ‘Embedder’ and a toolkit of resources for patients,
healthcare professionals and other key stakeholders.
The primary aim is, through increasing uptake to and attendance at SSME, to reduce HbA1c in people with T2DM
compared with usual care. Secondary objectives include: assessing whether there is an increase in referral to and
uptake of SSME and improvements in biomedical and psychosocial outcomes; an assessment of the sustainability of
the Embedding Package; contextualising the process of implementation, sustainability of change and the ‘fit’ of the
Embedding Package; and an assessment of the cost-effectiveness of the Embedding Package.
Discussion: This study will assess the effectiveness, cost-effectiveness and sustainability of the Embedding Package,
an intervention which aims to improve biomedical and psychosocial outcomes of people with T2DM, through
increased referral to and uptake of SSME.
Trial registration: International Standard Randomised Controlled Trials Number ISRCTN23474120. Assigned 05/04/
2018. The study was prospectively registered. On submission of this manuscript practice recruitment is complete,
participant recruitment is ongoing and expected to be completed by the end of 2019.
Keywords: Type 2 diabetes, Self-management, Structured education, Diabetes self-management, Diabetes
education, Randomised controlled trial, Wait-list, Cluster randomised trialBackground
Diabetes affects approximately 425 million people glo-
bally [1], with approximately 3.8 million in the United
Kingdom (UK) [2], a figure that continues to rise [3]. It
is estimated that by 2035, diabetes will account for 17%
of National Health Service (NHS) expenditure [4].
Around 90% of people with diabetes have Type 2 Dia-
betes Mellitus (T2DM) [1], a serious, progressive,
chronic disease, which leads to poor quality of life and
increased prevalence of costly long term health compli-
cations. Despite advances in pharmacological interven-
tions, management of T2DM remains a challenge.
Structured self-management education (SSME) for
T2DM has been shown to be both beneficial and cost-
effective [5–8]. Programmes such as DESMOND [6, 7],
X-PERT [8] and the Diabetes Manual [9–11], have
shown SSME to be associated with improved biomedical
(e.g. HbA1c, lipids, weight, blood pressure), psychosocial
(e.g. depression, quality of life, hypoglycaemia rates), be-
havioural, and medical outcomes [6–8, 12, 13]. A recent
systematic review and network meta-analysis found that
SSME on averaged reduced HbA1c by over 0.4%, with
the greatest benefits seen in those with poor glycaemic
control (HbA1c > 7.0%), aged less than 65 years and
non-white participants [14]. Powerfully, another system-
atic review combining data from 42 trials, found a 26%
reduced risk of all cause morality in those who had
attended diabetes SSME compared to standard care [15].
Unfortunately, despite the increase in the quality and
quantity of the evidence base since the National Institutefor Clinical Excellence (NICE) first recommended SSME
programmes and made SSME for T2DM a national pri-
ority in the UK [16], rates of uptake to SSME for those
with T2DM have remained persistently low. The recent
addition of a Quality and Outcomes Framework (QOF)
indicator for referral to SSME in those with newly diag-
nosed T2DM [17] has improved the rate at which educa-
tion is offered to people with newly diagnosed T2DM,
with 74.5% of those with newly diagnosed diabetes (type
2 and other) being offered SSME within 12 months of
diagnosis in 2016 as opposed to 47.4% in 2013 [18].
However, referral does not equate to uptake; moreover,
many of these programmes may not be evidence based
or meet the NICE criteria. The most recent national fig-
ures (2016) show that only 8.3% of T2DM patients were
recorded as having attended SSME within 12months of
diagnosis [18].
Evidence suggests that poor participation is due to
multiple patient, healthcare professional (HCP) and or-
ganisational factors. At the level of HCPs, barriers in-
clude: insufficient investment, insufficiently trained
educators, lack of staff capacity, absence of public health
marketing for diabetes awareness, lack of integration
into patient pathways, poor IT systems for tracking the
patient, absence of an infrastructure for organisation-
wide education, HCPs not advocating or recognising the
positive outcomes of self-management education, the
misperception that education is expensive, and lack of
consideration of patient access issues [19]. A review con-
ducted in 2017 highlighted a number of commonly
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cluded: issues with timing and length of courses; access/
transportation issues; family/work commitments; lack of
information and the benefits of attending not being
communicated by the HCP; patients feeling happy with
the information they had already been provided with
(and so seeing SSME attendance as unnecessary) [20].
An intervention titled the ‘Embedding Package’ has
been developed in order to increase uptake to SSME by
people with T2DM in primary care, with the overall
intention of improving glycaemic control. The Embed-
ding Package was designed to address barriers and en-
hance enablers to uptake at patient, HCP, and
organisation levels, including SSME providers and
commissioning bodies. This package has been piloted
and refined in a feasibility study (Davies et al. Increasing
uptake of self-management education programmes for
type 2 diabetes in a multi-ethnic primary care setting: A
feasibility study. 2019. In preparation). The mixed
methods study outlined in this protocol is designed to
assess the effectiveness, cost effectiveness, and sustainability
of this Embedding Package in comparison with usual care
using a wait-list cluster randomised controlled trial (RCT)
design with an integrated ethnographic study.
Methods/design
Objectives
The primary objective of this ambitious mixed methods
study is to assess whether the Embedding Package, by
increasing uptake and attendance at structured educa-
tion, reduces HbA1c in people with T2DM compared
with usual care. This objective will be addressed through
a wait-list cluster RCT.
The secondary objectives are to:
 assess whether the Embedding Package increases
referral to and uptake of structured education, as
well as improving biomedical and psychosocial
outcomes;
 assess sustainability of the Embedding Package using
an observational follow-up period;
 contextualise the process of implementation,
sustainability of the change and the ‘fit’ of the
Embedding Package within routine practice;
 assess cost-effectiveness of the Embedding Package.
Summary of study design
This 30 month open-label trial is testing a complex
intervention, the Embedding Package, compared to usual
care (see Table 1 for World Health Organization Trial
Registration Data Set). The intervention is complex with
elements delivered at multiple levels (practice, provider
and Clinical Commissioning Group (CCG)). The study
has been designed in line with best practice guidelines toseek to provide a comprehensive understanding of
whether and how the intervention works, as well as pro-
viding cost data to inform its potential roll-out in the fu-
ture [21]. Accordingly, the study comprises an 18month
wait-list cluster RCT, similar to a stepped wedge design
but with a single step during the study, to ascertain the
effectiveness and cost-effectiveness of the intervention,
followed by a 12month observation to ascertain whether
changes are maintained after study support is with-
drawn. This is a mixed methods project and to better
understand and evaluate the process of implementation,
ethnographic work will run alongside the trial.RCT design (months 0–18)
Baseline data have been collected at month 0. Practices
will be randomised 1:1 to 1) the immediate group who
receive the Embedding Package from months 0 to 18, or
2) the wait-list group who provide usual care for months
0–9 and receive the Embedding Package for months 9 to
18 (Fig. 1). Since data are collected from each step, each
practice acts as its own control (immediate group uses
the baseline data as its control, the wait-list group uses
data collected between 0 and 9months). To limit poten-
tial contamination, for the aspects of the intervention
that are targeted at CCG/locality/provider level (e.g. so-
cial marketing initiatives), we will request that as far as
possible, these are first targeted at practices participating
in the Embedding Package, and only aimed at wait-list
practices when these have crossed over to receive the
intervention.Observational follow-up design (months 18–30)
The 12-month observational follow-up is designed to in-
vestigate whether any improvements observed during
the RCT are maintained. During this time the study
team will no longer actively reinforce the Embedding
Package, but practices can continue using the interven-
tion provided during the RCT, if they choose to do so.Integrated ethnographic study (months 0–30)
The integrated ethnographic study is designed to provide
comprehensive data on the process of implementation
and the fit of the intervention. Qualitative data will be
gathered from observations and semi-structured inter-
views. The following will be undertaken:
1. Use the formative findings from the immediate
group to refine, tailor and enhance the Embedding
Package and its implementation in the second step.
2. Use the data to provide additional evidence about
the context of implementation and sustainability of
change in primary care
Table 1 World Health Organization Trial Registration Data Set
Item
Primary Registry and Trial
Identifying Number
International Standard Randomised
Controlled Trial Number, ISRCTN23474120
Date of Registration in
Primary Registry
05/04/2018
Secondary Identifying
Numbers
NA
Source(s) of Monetary or
Material Support
This project is funded by the National
Institute for Health Research (NIHR)
Programme Grants for Applied Research
(Increasing uptake of effective self-
management education programmes for
type 2 diabetes in multi-ethnic primary
care settings RP-PG-1212-20,004).
Primary Sponsor University of Leicester uolsponsor@le.ac.uk
Secondary Sponsor(s) NA
Contact for Public Queries Professor Melanie Davies
melanie.davies@uhl-tr.nhs.uk
Principal Investigator
Diabetes Research Centre, University of
Leicester, Leicester, UK.
Contact for Scientific
Queries
Professor Melanie Davies
melanie.davies@uhl-tr.nhs.uk
Principal Investigator
Diabetes Research Centre, University of
Leicester, Leicester, UK.
Public Title Evaluating the impact of increasing uptake
of self-management education pro-
grammes for Type 2 Diabetes in primary
care: A wait-list cluster randomised con-
trolled trial
Scientific Title Evaluating the impact of increasing uptake
of self-management education pro-
grammes for Type 2 Diabetes in primary
care: A wait-list cluster randomised con-
trolled trial
Countries of Recruitment UK
Health Condition(s) or
Problem(s) Studied
Type 2 Diabetes
Intervention(s) Intervention – Embedding Package
It comprises four key components: 1. clear
marketing strategy for SSME; 2. user
friendly and effective referral pathways; 3.
new/amended roles including a local
clinical champion and an ‘Embedder’; 4.
toolkit of resources (for patients, HCPs and
other key stakeholders).
Control – Usual Care
Eeach practice will continue to provide
their usual activities related to SSME whilst
in the control period.
Key Inclusion and
Exclusion Criteria
Patient Inclusion criteria: registered at a
participating practice; aged ≥18 years old;
coded in their primary care medical record
as diagnosed with T2DM before or during
the step (to be re-assessed at each data ex-
traction point). Patient exclusion criteria:
coded in their primary care medical records
as having a terminal illness, housebound or
in residential care; a dissent code in their
primary care medical records for researcher
to access clinical data.
Table 1 World Health Organization Trial Registration Data Set
(Continued)
Item
See eligibility section for full inclusion/
exclusion for all parts of the study.
Study Type Type of study - interventional
Method of allocation – cluster randomised
Masking – none
Assignment – wait list study, practices
randomised 1:1 to immediate intervention
or to wait
Purpose – improve outcomes
Date of First Enrolment First practice 06/08/2018
Target sample size 66 practices
2050 participant questionnaires
Recruitment status As of 02/10/19 66 practices recruited, 1920
questionnaires returned
Primary outcome(s) HbA1c
Key secondary outcomes Referral and uptake rates to SSME
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embed SSME has continued in the observational
follow-up period
4. Examine the extent to which changes are perceived
to have been sustained
5. Identify any changes in the stakeholder
organisations with a bearing on sustainability.
Cost estimates will also be generated from structured
interviews with staff from SSME providers. The interview
and observational data collection tools were developed
and tested in the preceding feasibility study (Davies et al.
Increasing uptake of self-management education
programmes for type 2 diabetes in a multi-ethnic primary
care setting: A feasibility study. 2019. In preparation).
Primary and secondary outcome measures
All outcomes will be measured at baseline (0month), first
(0–9months), and second (9–18months) steps, as well as
over the observational follow-up (18–30months), except
for the self-report data which will only be measured once
by questionnaire (during the first step). All biomedical
patient level outcomes will be extracted from primary care
electronic medical records. For most of these outcomes,
the last measurement within that time period will be used.
For example, for the first step HbA1c will be defined as
the last HbA1c measurement between months 0 and 9. If
the variable has not been measured over that time period
then it will be deemed missing.
Primary outcome
The primary outcome is patient-level HbA1c compared
between the control and intervention conditions in the
RCT i.e. the baseline measure in the immediate group,
and baseline and first step in wait-list group compared
Fig. 1 Outline of the design of the trial
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ond step in wait-list group.
Secondary outcomes
The secondary biomedical measures to be extracted
from primary care at the patient level are: Body Mass
Index (BMI); weight; total, Low-Density Lipoprotein
(LDL) and High-Density Lipoprotein (HDL) cholesterol;
systolic and diastolic blood pressure; glucose, blood
pressure and lipid lowering medications; smoking status;
hospital admissions; cardiovascular risk score.
Process outcomes will reflect how the intervention is
implemented and aid understanding of effectiveness.
They will be measured at the patient, practice, or pro-
vider level as appropriate, and will include the following:
whether or not the patient was referred to and attended
SSME (main secondary outcome); type of SSME; per-
centage of eligible individuals referred to education; per-
centage of eligible individuals who attended education;
percentage of eligible individuals who declined educa-
tion; number, timing and venue of available education
sessions; number of trained educators.
Secondary psychosocial and process outcomes will also
be self-reported by a subset of patients at a single time-
point during the first step so that psychosocial outcomes
can be compared between those in the intervention and
control arms (it is estimated around 2000 questionnaires
will be returned). This data will be collected by ques-
tionnaire; all participants will be sent a short question-
naire they can further opt to complete an additionalquestionnaire. The self-reported outcomes from the
short questionnaire are: whether or not the patient was
referred to and attended SSME; and where the patient
has previously received diabetes information from.
Those completing the additional questionnaire will pro-
vide data on patient activation measure; well-being (W-
BQ12); Problem Areas in Diabetes (PAID) score.
Additionally, back end website data on the extent of
user engagement (e.g. length of time for which individ-
ual pages were viewed and the number of occasions etc.)
with specific tools in the online toolkit will be collected.
Trial participants
Recruitment
Before patients were contacted CCGs and their associ-
ated SSME providers were approached regarding the
study. They needed to support the study by implement-
ing the aspects of the Embedding Package that are aimed
at providers and commissioners themselves. Participat-
ing providers will contribute data on activities relating to
the Embedding Package for use in the cost-effectiveness
analysis, on the availability of education sessions and on
the number of educators. In CCGs where the provider
declined participation, Embedders will work solely and
directly with the practices.
Eligible practices within these localities were recruited.
Practices with an interest in taking part will contact the
research team to discuss their possible participation.
Patient-level data will be extracted from participating
practices computer systems. Cost-effectiveness data will
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age activity. All patients diagnosed with T2DM at the
start of each step (including those diagnosed during the
step), registered at the practice, and meeting the eligibil-
ity criteria will have their pseudonymised data extracted
for the outcome measures and will be invited to
complete a consent form to link extracted data with self-
reported information.
Sampling to the integrated ethnographic study will be
purposive, and based on practice characteristics (loca-
tion, type of setting - rural, suburban or urban, practice
size and socio-economic factors), provider characteristics
(structured education programme) and CCG characteris-
tics (sustainability and transformation plans) [22]. Adop-
tion of this selection criteria will enable the
identification of a varied sample of practices with a view
to developing an in-depth explanation of the extent of
success of implementing the Embedding Package at dif-
ferent levels and in different settings, and inform how to
optimise implementation of the package (and similar ini-
tiatives) in different contexts. In the first step, this will
be informed by demographic profile and discussions
with the trial co-ordinators, and will aim to generate a
maximum variation sample [23]. Sampling during the
second step will be theoretically informed by mid-term
progress data to explore the challenges involved in
implementing and sustaining the Embedding Package in
a variety of circumstances. Data will also be collected
from organisations associated with the delivery of the
Embedding Package in these practices, including CCGs,
providers, NHS England regional offices, area teams, and
commissioning support units. Practices and associated
organisations sampled in the first step will continue to
be included in data collection in the second step.
A sub-sample of practices and all of the participating
providers will also provide more detailed information on
the costs of the individual activities through interviews
with a designated staff member (such as the SSME ser-
vice manager).
Practice recruitment is complete. The first practice
was randomised on 06/August/2018, the last practice
was randomised on 22/February/2019. Data collection
will be completed by 22/August/2021. Participant re-
cruitment started in August 2018 and is expected to be
completed by December 2019.
Eligibility criteria
Practices, patients and stakeholders will be recruited and
take part in relevant study activities if they meet all of
the relevant criteria, as detailed below.
Practices
Practice should be located within a participating CCG;
use either EMIS Web or TPP SystmOne (required fordata extraction); able to refer people with T2DM to a
structured education programme which meets NICE cri-
teria; willing to sign a data sharing and data collection
agreement with PRIMIS allowing the collection of pseu-
donymised patient data and, where patient consent is
given, identifiable data, as required for analysis; where
appropriate willing to have a sample of meetings and
consultations observed or to be interviewed.
Patients – data extraction and mail-out
All patients registered at a participating practice and
meeting the following eligibility criteria will have pseu-
donymised data extracted. Eligibility will be assessed at
each step and therefore the study is of an open cohort
design. If included patients die, or leave the practice,
they will be included up until this point. All eligible pa-
tients at baseline will be invited to join the self-report
component and consent to link data.
Patient inclusion criteria: registered at a participating
practice; aged ≥18 years old; coded in their primary care
medical record as diagnosed with T2DM before or dur-
ing the step (to be re-assessed at each data extraction
point); willing and able to provide informed consent (ap-
plicable to optional consent form and questionnaire
booklet only); able to understand written English to a
level sufficient to enable an understanding of the
research and their participation within it (applicable to
optional consent form and questionnaire booklet only).
Patient exclusion criteria: coded in their primary care
medical records as having a terminal illness, housebound
or in residential care; a dissent code in their primary care
medical records for researcher to access clinical data.
Patients – integrated ethnographic study
Patients who express an interest to participate in the
ethnographic study and meeting the following criteria
will be eligible for the ethnographic study. Patient inclu-
sion criteria: meet all of the patient eligibility criteria for
the trial; is able to attend the practice unaided or with a
carer or support (applicable to observations of consulta-
tions only). Patient exclusion criteria: unable to understand
spoken English to a level sufficient to enable an under-
standing of the research and their participation within it.
Stakeholders
Stakeholders are individuals who work at participating
practices, members of CCGs, education providers, or in
attendance at meetings in a patient and public involve-
ment (PPI) capacity, who may be approached to partici-
pate in a number of activities. Stakeholders will be
eligible for inclusion in the integrated ethnographic
study if they meet all of the following inclusion/exclu-
sion criteria. Stakeholder inclusion criteria: employed by
a participating practice/CCG/provider organisation, or
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of the Embedding Package in a participating practice/
CCG/provider organisation; willing and able to give in-
formed consent (written or verbal). Stakeholder exclu-
sion criteria: unable to understand written and spoken
English to a level sufficient to enable an understanding
of the research and their participation within it.Study procedures
Informed consent
Informed consent will not be required for the data ex-
traction element of the study as patients will not be dir-
ectly approached and their data will be extracted
pseudonymously. However, the Caldicott Guardian of
each participating practice will be required to consent to
the extraction. A summary of the method of consent for
each study element is provided in Table 2.
All members of the research team receiving informed
consent will be Good Clinical Practice certificated, and
authorised to do so by the Chief Investigator. Original
signed consent forms will be retained and participants
will be given or sent a copy. The PIS will detail the exact
nature of the study, the implications, and any risks in-
volved in taking part.Consent to complete questionnaire booklet and link with
routine clinical data
Patients will be approached by postal invitation sent
from the practice along with information about the
study and a questionnaire booklet containing a short
questionnaire and consent form. Patients will also be
asked to provide consent for the research team to link
their responses to the data extracted from GP practices
and their record held by the local SSME provider, if such
a record exists. Patients will be able to decline participa-
tion, or to indicate willingness to participate in either
the self-report and data linkage (participation in one of
these does not necessitate participation in any other ac-
tivity). Patients could also opt to complete an additional
questionnaire which included patient reported outcome
measures.Table 2 Summary of method of consent per study element
Study Element Method of Consent
Complete questionnaire booklet and link
with routine clinical data (patients)
Written via mail-out
Interviews - Face-to-Face Written
Interviews - Telephone Verbal
Observations - SSME Session Written
Observations – Consultations/Meetings VerbalConsent to interviews
Informed consent will be received by a member of the
research team when a patient or stakeholder agrees to
participate in an interview. All participants will have the
opportunity to discuss the purpose of the interview and
the PIS, ask any questions they have, and then to decide
whether they will participate. For face-to-face interviews,
the interviewer will obtain written informed consent im-
mediately prior to the interview. For telephone inter-
views, the interviewer will audio record the reading out
of the latest approved version of the consent form and
the participant’s agreement with clauses, the consent
form will then be annotated with the recording identifi-
cation code, signed, and dated by the interviewer. The
original copy of the consent form will be retained in the
study file and a copy will be provided, either at the time
of the interview or by post, to the participant.
Consent to observation of SSME sessions
The educator(s) of a sample of one-to-one or group-
based SSME sessions will be given a copy of the stake-
holder PIS and will have the opportunity to consider this
information and ask any questions. They will then be
asked to provide written consent and confirm the dates
of the sessions they would be happy to have observed. If
the educator(s) does not consent then no participants
will be approached. After educator consent has been re-
ceived, when booking participants onto one of these ses-
sions, the SSME administrator will inform each
participant verbally about the study and the presence of
an observer. If a participant does not want to attend a
session that is being observed, they will be booked onto
a session on an alternative date. Participants who give
verbal consent (when booking) to be observed will be
sent a PIS. Immediately prior to the session, a verbal de-
livery of the PIS will be given by the researcher. Prior to
requesting written consent, potential participants will be
given the opportunity to have any questions related to
the study or their participation within it addressed.
Consent to observation of healthcare consultations
The ethnographic team will attend clinics in order to ob-
serve consultations where discussions about SSME may
take place between patients and HCPs. It will not be
practical or appropriate to obtain written consent from
the HCP or the patient on the day, as this would present a
burden to the practice and introduce delays in the clinic/
appointment schedule. Therefore, verbal permission will
be obtained from the patient and the HCP ensuring that
those who wish to opt out can easily make this known.
Written and verbal versions of the PIS will be provided
and all participants will be given time to consider the in-
formation and ask questions. Patients will be informed of
the possible presence of an observer by the practice
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be made clear that they are free to ask that their consult-
ation is not observed. The observer will offer to withdraw
without any reason having to be given by either the pa-
tient or the HCP, and in any event will withdraw if there
is any doubt about the appropriateness of their presence.
Consent to observation of practice/provider meetings
A sample of meetings where SSME is discussed may be
observed. Verbal consent will be sought from the appro-
priate person in the organisation and/or the Chair of the
meeting. When possible, those due to attend the meet-
ing will be informed about the study by the observer
prior to the meeting, by providing them with a copy of
the stakeholder PIS. If the Chair is willing, at the start of
the meeting the observer will explain their role, that
anonymity is guaranteed and that they will absent them-
selves at any time if anyone would rather they were not
there; they will then receive verbal consent from all
those present. If any individual does not wish to give
consent, the observer will withdraw from the meeting.
Participants may also request that the observer with-
draws temporarily, for example if part of the meeting re-
lates to issues that are confidential, or are not pertinent
to the focus of the study. The researcher will respect all
such requests.
Data collection
Provider-level process outcome data will be collected
from the provider using a brief questionnaire at months
0, 9, 18, and 30. Patient-level biomedical and process
outcome data will be collected through pseudonymous
extraction from primary care data using Read codes.
These data will be aggregated where appropriate to cal-
culate the practice-level process outcomes. Data will be
extracted at three time-points (month 0, month 9 and
18 collected together, and month 30).
Data extraction procedures are based on those used
previously in similar studies [24], and the preceding
feasibility study (Davies et al. Increasing uptake of self-
management education programmes for type 2 diabetes
in a multi-ethnic primary care setting: A feasibility study.
2019. In preparation). Practices can extract their own
data, pseudonymise it and then transfer it electronically
to the study team at the University of Leicester, or this
can be done remotely by PRIMIS. Data extraction will
be performed using MIQUEST software. The only key
identifier to be extracted will be NHS numbers which
will be encrypted into a unique hash (#) code by an
Open-Pseudonymiser and CHART software and stored
in a spreadsheet containing only pseudonymised data.
This will be appropriately and securely transferred to the
research team at University of Leicester. PRIMIS will not
be able to identify patients at any point during the study.The practice ID code will not be encrypted as it will be
required by the study team to identify which randomisa-
tion arm the data belong in.
The transferred spreadsheet will contain one line per
patient pseudonymised data from all people with T2DM
registered at the participating practices during each step
(See Table 3). Data recorded over the measurement pe-
riods (months 0, 0–9, 9–18, and 18–30) will be
extracted.
Each questionnaire booklet sent to patients via a prac-
tice mail shot will be pre-assigned a unique patient iden-
tifier. Consent and patient details (NHS number, patient
name and contact details) will be collected on a separate
form and will be stored separately. If the questionnaire
booklet is completed and returned with consent, the
NHS number will be used to identify the individual pa-
tient data in the data extracted from primary care. PRI-
MIS will provide the study team with the encryption
algorithm so a NHS number can be converted to the
unique hash (#) code to allow this linkage. Additionally,
if consent is given, the list of names and NHS numbers
of patients will be cross-checked against relevant pro-
vider systems, and data on SSME invitation and attend-
ance held by the provider for these individuals will be
linked with their GP and self-report data. The study
team will only have access to the name and NHS num-
ber of patients returning their questionnaire booklets
and will only link data of consenting patients. Secure
NHSmail service will be used. Patient NHS numbers will
be sent between NHSmail and NHSmail addresses. In
addition, list of patients’ NHS numbers will be password
protected and passwords will be sent in a separate email.
The flow of patient data is shown in Fig. 2.Integrated ethnographic study
Ethnographic data collection is likely to include observations
of: ‘usual care’; implementation of the Embedding Package;
and observations of the operationalisation of the Embedding
Packing in a variety of local contexts. This will include infor-
mal discussions with healthcare, commissioning, and admin-
istration staff, the collection of key documents, including
publically available information, and structured field notes,
[25]; semi-structured interviews (involving stakeholders in-
volved in commissioning, training and implementing SSME
and/or the Embedding Package, and people with T2DM).
Interviews will explore perceptions and experiences related
to the various elements of the Package, and preferred
modalities of SSME (such as group-based, one-to-one or on-
line). Interviews will last approximately 30–45min and may
be conducted at their place of work, home, another conveni-
ent location, or by telephone, depending on participant pref-
erence. All interviews will be audio-recorded (with
participant consent) and transcribed.
Table 3 Data extracted from primary care at each time point
Variable Value of Interest To be extracted
Type 2 diabetes diagnosis First recorded Value and date
NHS number Last recorded Pseudonymised value
Age Last recorded Value
Sex Last recorded Value
Ethnicity Last recorded Value
Smoking status Last recorded Value and date
SSME: Referred Last recorded Value and date
SSME: Not suitable Last recorded Value and date
SSME: Declined Last recorded Value and date
SSME: Did not attend Last recorded Value and date
SSME: Not completed Last recorded Value and date
SSME: Attended Last recorded Value and date
SSME: Completed Last recorded Value and date
HbA1c Last recorded within measurement period Value and date
Body mass index Last recorded within measurement period Value and date
Weight Last recorded within measurement period Value and date
Height Last recorded Value and date
Total cholesterol Last recorded within measurement period Value and date
LDL cholesterol Last recorded within measurement period Value and date
HDL cholesterol Last recorded within measurement period Value and date
Systolic blood pressure Last recorded within measurement period Value and date
Diastolic blood pressure Last recorded within measurement period Value and date
Cardiovascular risk score Last recorded within measurement period Value and date
Medication: Glucose lowering All recorded within measurement period Value and date
Medication: Lipid lowering All recorded within measurement period Value and date
Medication: Blood pressure lowering All recorded within measurement period Value and date
Hospital admission All recorded within measurement period Value and date
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The ‘Embedder(s)’ (i.e. the person(s) responsible for
driving the implementation of the Embedding Package)
will complete a simple tick-box tracker of the pre-
identified implementation activities for months 0–9, 9–
18 and 18–30. This tracker will cover the type of activity,
the duration over which it was applied, and whether it is
still ongoing, providing a census of what activities have
been attempted. In addition, the tracker data will pro-
vide a measure of resource use against which unit costs
can be applied to estimate the costs associated with the
Embedding Package. The unit costs will be generated by
structured interviews undertaken with designated staff at
provider organisations within a sub-sample of practices.
The interview will ask for details of staff time, consumables,
and other costs that have been devoted to each individual
activity over the duration that the activity was undertaken.
A pro-forma for the activity data requirements will be sent
in advance of the interview. A follow-up e-mail to confirmthe data discussed at the meeting will be sent to the inter-
viewees. A maximum of two further e-mails will be sent to
resolve any outstanding data queries. Resource use and
costs data for developing the intervention, the Embedding
Package, will be obtained from the study team.
Intervention
The Embedding Package underwent development based
on a range of qualitative and experiential work, as well
as piloting in an earlier feasibility (Davies et al. Increas-
ing uptake of self-management education programmes
for type 2 diabetes in a multi-ethnic primary care setting:
A feasibility study. 2019. In preparation). It comprises
four key components: 1. clear marketing strategy for
SSME; 2. user friendly and effective referral pathways; 3.
new/amended roles including a local clinical champion
and an ‘Embedder’; 4. toolkit of resources (for patients,
HCPs and other key stakeholders). The toolkit contains
a wide selection of patient-facing resources (e.g.
Fig. 2 The flow of patient data
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forms), HCP-oriented resources and guidance (e.g. docu-
ment templates, guidance for recruiting staff, referring
patients and increasing staff engagement) and coordin-
ation/provider/commissioner-oriented resources (e.g.
audit collection and reporting, electronic administration
and referral systems, and sample referral pathways). It
will also include guidance on constructing and carrying
out marketing and communication strategies, how to
carry out local needs assessments, as well as detail about
how to ensure patient accessibility and course tailoring.The new/amended roles will include the appointment of
an ‘Embedder’ working across each site (or potentially
up skilling of an individual already holding an analogous
post) who will liaise between all relevant stakeholders to
promote SSME, use of the Toolkit, communication and
referrals etc. A local clinical champion in each CCG (for
example the Diabetes Lead at one of the participating
practices) will be identified to promote SSME across the
whole locality. Together the two roles and the online
Toolkit make up the ‘Embedding Package’ (the
intervention).
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SSME as a complement to attendance at the group-
based version as some patients may prefer education de-
livered via a different modality. In order to track the use
of this, practice-specific log-ins will be generated that
participating practices can give to patients. There will be
posters in participating practices to make patients aware
of this option.
To allow for any changes to the landscape of the NHS
during the project, whilst maintaining the integrity of
the study, any changes to the Embedding Package will
only be made at Month 9, i.e. when the wait-list group
begin receiving the intervention, so that the Embedding
Package received during any one time period is consist-
ent. The details of the Embedding Package that is actu-
ally delivered in each time period will be recorded and
considered in secondary analyses, as appropriate.
On commencement of the study in a CCG, the
Embedder will hold a Toolkit Action Plan meeting to
look at which elements of the Toolkit can be imple-
mented. This will then be written up and circulated for
finalisation including assigning of tasks to relevant
personnel. Review meetings will be scheduled to look at
progress. Actions relating to practices will then be dis-
seminated by the ‘Embedder’ to the relevant staff within
each practice, and additional meetings arranged, if
necessary.
Control
Usual care will be practice-dependent; therefore, each
practice will continue to provide their usual activities re-
lated to SSME whilst in the control period. These activ-
ities vary greatly between CCGs and their associated
practices, and due to the ever-changing landscape of the
NHS, usual care may evolve over time. However, usual
care will be monitored and recorded within all practices.
Randomisation
This is an open-label trial as it will not be possible to
blind practices to their treatment arm. Practices will be
randomised prior to baseline (month 0) in a 1:1 fashion
to either: Immediate group (receive the Embedding
Package for months 0–18), or wait-list group (provide
usual care for months 0–9 then receive the Embedding
Package for months 9–18). Randomisation will be strati-
fied by CCG, and generated and implemented by a stat-
istician. The statistician will provide the study team with
the randomisation outcome so that they can inform
practices of their allocation.
Analysis methods
RCT
Data from the RCT will be analysed once data collection
is complete. Descriptive summary statistics of baselinecharacteristics and process variables (e.g. number of
education sessions available, back end data for the Tool-
kit and MyDesmond websites, usual care delivery, etc.)
will be produced, using mean (standard deviation) for
normally-distributed variables, median (interquartile
range) for non-normally distributed variables, and count
(percentage) for categorical variables.
The primary analysis will compare HbA1c between the
control and intervention states using a mixed model that
allows for repeated longitudinal outcomes and practice-
level clustering, and is adjusted for season to deal with
expected seasonal variation in HbA1c. The primary ana-
lysis will be based on the intention-to-treat (ITT) popu-
lation, i.e. all eligible patients will be included. Missing
outcome data will need to be imputed for the ITT ana-
lyses. This will be done using an appropriate multiple
imputation method; it is anticipated that predictive
mean matching will be used to impute continuous out-
comes as this is able to handle non-linearity and non-
normality, and logistic regression will be used for binary
outcomes. Predictive variables are likely to include prac-
tice level demographics, e.g. sex, ethnic group, or base-
line HbA1c. Sensitivity analyses will repeat the primary
analyses using complete cases and per protocol
populations.
As secondary analyses, the ITT model from the pri-
mary analysis will be fitted for the following subgroups
of interest: (1) including only patients who attended edu-
cation; (2) excluding patients with HbA1c < 6.5% at
baseline; (3) by baseline education attendance status; (4)
by patient ethnicity and age to examine the effectiveness
of the Embedding Package in groups in which there is
low SSME uptake; (5) by type/format of programme of-
fered/attended.
Secondary patient-level and practice-level outcomes
will be compared in a similar manner to the primary
analyses, except that practice-level outcomes will not be
adjusted for cluster and the psychosocial outcomes will
not account for repeated measures as they will only be
measured once.
Summaries of self-reported referral and attendance
will be produced using appropriate descriptive statistics
for the whole dataset and by pertinent subgroups, such
as sex and age. Data on SSME referrals and attendance
will also be compared between data sources (i.e. self-
report, practice, and provider).
A full statistical analysis plan will be written and
agreed by all investigators and the trial steering commit-
tee before the data are released for analysis. Statistical
significance will be defined as p-values less than 0.05.
Observational follow-up
Summaries of the outcomes measured in the observa-
tional follow-up will be produced using appropriate
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pared with the HbA1c estimates under intervention and
control conditions in the RCT using mixed regression
models accounting for repeated measures on the same
patients and for the practice-level clustering. Similar
analyses will be conducted for the secondary outcomes,
including the process outcomes which will aid under-
standing about why changes are, or are not, sustained.
Integrated ethnographic study
Qualitative data will be analysed using the Framework
Method [26]. Data will be coded and organised based on
an established model for evaluating intervention design:
Normalisation Process Theory (NPT) [27, 28]. Findings
from the ethnographic work will be triangulated with
quantitative data [29] to provide an in-depth and inte-
grated explanation of the process of implementing the
Embedding Package in a variety of contexts. The adop-
tion of an inductive and reflexive approach will ensure
rapid development and integration of findings from the
earlier stages, and inform the optimisation of imple-
menting the intervention, particularly in relation to
sustainability.
Cost-effectiveness analysis
The general framework for the analysis is to describe the
costs and effects of current levels of implementation
using published estimates of the cost-effectiveness of pa-
tient education programmes, then estimate the incre-
mental costs and benefits of increased implementation.
These incremental costs and benefits will be a combin-
ation of the costs of the implementation activities, the
associated increase in uptake and the cost effectiveness
of the patient education programmes. This framework
has been applied to implementation of QOF indicators
[30] and is currently being developed further by the De-
partment of Health Policy Research Unit for the Eco-
nomic Evaluation of Health and Care Interventions
(EEPRU).
The cost-effectiveness analysis will take an NHS per-
spective and model costs and effects over the lifetime of
patients (with appropriate discounting). The costs of im-
plementation activities will be generated from within the
RCT. The Embedders will record all activity and the up-
take of individual embedding activities in each provider
will be recorded through an activity proforma, whilst
unit costs for each activity will be generated via inter-
views in all providers across a sample of practices. The
resources identified in each interview will be costed
using either budget information from the practices/
CCGs or external unit costs (e.g. Unit Costs of Health
and Social Care). All other costs relating to diabetes care
will be generated by the Sheffield T2DM policy model
[31, 32] which will have its data sources updatedthrough literature review and identification of the most
recent unit costs.
The effects of the implementation activities will be
measured in terms of quality adjusted life years (QALYs)
estimated using the Sheffield T2DM policy model. The
model will generate the QALYs via changes in HbA1c
associated with SSME. Changes in HbA1c will be esti-
mated in two ways. The primary analysis will be based
on individual patient data from this RCT (as described
above), whilst a secondary analysis will use published es-
timates of the effectiveness of SSME generated from a
meta-analysis of RCT data. The central estimate of the
incremental cost-effectiveness ratio of the Embedding
Package will be presented, together with probabilistic es-
timates of cost-effectiveness represented in a cost-
effectiveness acceptability curve. Value of information
analysis will be undertaken using the Sheffield Acceler-
ated Value of Information tool [33]. Deterministic sensi-
tivity analysis will also be undertaken to explore the
effects of uncertainties that cannot be adequately repre-
sented probabilistically; for example, the length of effect
of the package, uptake rate without the package, and the
mix of alternative education programmes to which pa-
tients are referred. Methods and results will be reported
in line with Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) recommendations [34].
Sample size
In the feasibility study an average cluster size of 460 was
found across the six practices included (range 118–824)
(Davies et al. Increasing uptake of self-management
education programmes for type 2 diabetes in a multi-
ethnic primary care setting: A feasibility study. 2019. In
preparation). Recruiting 58 practices (29 to each randomisa-
tion point) will give over 90% power to detect a difference in
HbA1c of 0.1% assuming an SD of 1.5%, based on United
Kingdom Prospective Diabetes Study (UKPDS) [35]. There
will be 80% power to detect a difference as small as 0.062%.
This assumes an intra-cluster correlation coefficient (ICC) of
0.05, one baseline HbA1c measurement with one more
HbA1c measurement at each randomisation point. This cal-
culation does not take account of potential variation in clus-
ter size, as methodological work has shown that the power
of studies of a stepped wedge type design is robust to vari-
ation in cluster size [36]. The sensitivity of this calculation to
changes in the average cluster size was assessed. As long as
the average cluster size remains larger than 174 there will be
80% power to detect a 0.1% difference. To allow for potential
cluster drop out of 10% the target will be to recruit 66 prac-
tices in total.
Return of a completed questionnaire booklet (self-re-
port questionnaire and/or consent to link data form) will
be recorded as consent to participate in the study. Add-
itionally stakeholders and patients consenting to
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corded as participants. It is anticipated a minimum of
2050 participants will be recruited (2000 via question-
naire and 50 via interview/observation).
The integrated ethnographic study will be conducted
within a sub-sample of approximately 12 of the practices
and related contexts (e.g. CCGs and providers). Purpos-
ive sampling of practices will take place in the first and
second steps of the RCT to ensure a representative sam-
ple [22]. A subset of 12 practices will provide data for
the cost-effectiveness analysis.
Dissemination
The team have a strong track record in generalising,
disseminating and implementing research findings.
Locally, results will be shared with primary and secondary
healthcare organisations, public health bodies and local
authorities. The community will be informed of key
findings via a multimedia campaign using high profile
public venues and services, local press, and accessible
social media.. Local ethnic and cultural communities will be
contacted through PPI groups and specialist local media.
Nationally, results will be submitted for publication in
peer-reviewed journals and to the NIHR Library and for
presentation at NHS, health policy, commissioning, dia-
betes and nursing conferences, to achieve wide dissemin-
ation to academic and clinical communities. The
researchers will link with key NHS stakeholders (The
Royal College of General Practitioners, the East Mid-
lands Academic Health Science Network, The King’s
Fund, the Strategic Clinical Network, the Health Foun-
dation, the South Asian Health Foundation, and the
NIHR, particularly Applied Research Centres, and Aca-
demic Health Science Networks) specifically with imple-
mentation in mind, holding regional events for NHS
stakeholders. Findings appropriate to the general public
will be disseminated through public organisations, na-
tional and local diabetes, third sector, the national
Healthwatch network, and Diabetes UK. In consultation
with PPI groups, we will take direction for prioritising
methods of sharing key findings through popular media,
through public information networks, and web-based
technology. Evaluation of the impact of our communica-
tions strategy will be made through analysing the num-
ber of publications covering outcomes, web page hits
and other success measures.
Programme steering committee
A Data Monitoring Committee was not set up for this
study given the low risk nature of the intervention, i.e.
the intervention is aiming to increase uptake to estab-
lished programmes which are recommended by NICE.
An independent Programme Steering Committee has
been appointed and agreed by the funders.Discussion
This mixed methods study will assess the effectiveness,
cost-effectiveness and sustainability of the Embedding
Package, an intervention which aims to improve biomedical
and psychosocial outcomes of people with T2DM, through
increased referral to and uptake of SSME. This study is
timely. In 2017 the James Lind Alliance published the top
ten research priorities in Diabetes, and the question “What
is the best way to encourage people with type 2 diabetes,
whoever they are and wherever they live, to self-manage
their condition, and how should it be delivered?” was
ranked third, highlighting the importance of this issue to
patients with T2DM, carers, health-care professionals, and
ethnic minority groups [37]. Given the high burden of
disease and the current low levels of uptake to education,
this study has the potential to have a big impact on the
management of T2DM within the UK.
This trial is informed by a programme of work in-
cluding development of the Embedding Package based
on evidence from existing studies to identify experien-
tial practices, procedures, strategies and plans which
represent best practice. A feasibility study was then
conducted which gave an opportunity to pilot the inter-
vention and refine it based on ethnographic findings
and to assess the feasibility of data collection processes.
The results of the pre-trial studies are described in
detail elsewhere (Davies et al. Increasing uptake of self-
management education programmes for type 2 diabetes
in a multi-ethnic primary care setting: A feasibility
study. 2019. In preparation).
The trial not only assesses the effectiveness of the
intervention but also includes an observational follow up
phase. During this time no active trial input will happen,
and the follow-up phase will therefore capture whether
the Embedding Package can change culture and practice
leading to longer term improvements. The trial is also
pragmatic; all people with T2DM will be included irre-
spective of whether they are referred to or attend educa-
tion during the study period. Therefore a small change
in HbA1c is expected. In a study conducted at the pa-
tient level, a minimum difference of 0.3% in Hba1c may
be clinically meaningful and lead to change in practice.
Here the study is powered to detect a difference of at
least 0.1%. This reflects the practice-level design of the
study. Planned secondary analyses will try to elicit the
effectiveness of the intervention in those referred to edu-
cation during the course of the study. The study uses a
wait-list design, similar to a stepped wedge design but
with a single step during the study. The design is effi-
cient as each practice acts as its own control and there-
fore produces a significant reduction in the sample size
required compared to a standard cluster randomised
trial. Given components of the intervention are delivered
at the level of the CCG/providers, strategies to limit
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place during the first step.
If the Embedding Package is found to be both effective
and cost-effective, a ‘toolkit’ to enable widespread imple-
mentation will be developed and rolled-out.
Abbreviations
BMI: Body mass index; CCG: Clinical Commissioning Group;
DESMOND: Diabetes Education and Self-Management for On-going and
Newly Diagnosed; HCP: Healthcare professional; HDL: High-density
lipoprotein; ICC: Intra-cluster correlation coefficient; LDL: Low-density
lipoprotein; MRC: Medical Research Council; NHS: National Health Service;
NICE: National Institute for Health and Care Excellence; NPT: Normalisation
Process Theory; PPI: Patient and public involvement; QOF: Quality and
Outcomes Framework; RCT: Randomised controlled trial; SSME: Structured
self-management education; T2DM: Type 2 diabetes mellitus; UK: United
Kingdom; X-PERT: X-PERT Health Diabetes Education Programme
Acknowledgements
The authors also acknowledge support from the National Institute for Health
Research Collaboration for Leadership in Applied Health Research and Care
— East Midlands (NIHR CLAHRC — EM) and the NIHR Leicester Biomedical
Research Centre, which is a partnership between University Hospitals of
Leicester NHS Trust, Loughborough University and the University of Leicester.
Authors’ contributions
MJD, CAK, AA, SD, HE, AG, LH, NH, KK, GM, AN, MP, RP, SS, BS, JT, LJG made
substantial contributions to conception and design, or acquisition of data, or
analysis and interpretation of data. All authors read and approved the final
manuscript.
Funding
This project is funded by the National Institute for Health Research (NIHR)
Programme Grants for Applied Research (Increasing uptake of effective self-
management education programmes for type 2 diabetes in multi-ethnic pri-
mary care settings RP-PG-1212-20004). The views expressed are those of the
authors and not necessarily those of the NIHR or the Department of Health
and Social Care. The funder had no involvement in the study design, con-
duct, or manuscript writing.
The Trial Sponsor is the University of Leicester uolsponsor@le.ac.uk.
Availability of data and materials
Not applicable.
Ethics approval and consent to participate
The NHS Research Ethics Committee West Midlands - Edgbaston has
provided ethical approval for the conduct of this study (REC reference: 18/
WM/0036). HRA Approval was issued on 05 February 2018.
All methods of consent were approved by the Ethics Committee. The
Caldicott Guardian of each participating practice gave to consent to the data
extraction from primary care. Return of a completed questionnaire will be
taken as implied consent. Patients will also be asked to provide written
consent for the research team to link their responses to the data extracted
from GP practices and their record held by the local SSME Provider, if such a
record exists. Additionally, consent will be taken by the researcher before to
the start of the interview or the observation.
The current protocol version is Version 3; 23 April 2019. Two substantial
amendments have been approved. Substantial Amendment 1 changes were
based on feasibility study findings and entailed a revision of sample size,
study paperwork and how data is collected. Substantial Amendment 2
involved changes to practice eligibility criteria, to clarify that ethnographic
sub-study is optional and to increase study target, due to the greater than
anticipated number of questionnaires being returned by patients.
Consent for publication
Not applicable.
Competing interests
Conflicts of interest: We do not hold any conflicts of interest, however, for
transparency we provide the following statement of conflict: MJD is thePrincipal Investigator (PI) on the DESMOND programme (Diabetes education
and self-management for people with newly diagnosed Type 2 diabetes). BS,
SS and AN are employed by the University Hospitals of Leicester NHS Trust,
which receives not-for-profit income for DESMOND. MJD, KK, HE, LG, AN, SS
and BS are actively engaged in research and have previously received grants
for DESMOND from NIHR, MRC and Diabetes UK to develop and test Dia-
betes Self-Management Education and Support programmes like DESMOND.
The University Hospitals of Leicester (UHL) NHS Trust (for which BS, SS and
AN have a contract) receives licensing fees to support implementation of the
DESMOND programme in CCGs in the UK, Ireland and Australia.
All other authors have no competing interests.
Author details
1Diabetes Research Centre, University of Leicester, Leicester, UK. 2Leicester
Diabetes Centre, University Hospitals of Leicester NHS Trust, Leicester, UK.
3Biostatistics Research Group, Department of Health Sciences, College of Life
Sciences, University of Leicester, George Davies Centre , University Road,
Leicester LE1 7RH, UK. 4School of Health and Related Research, University of
Sheffield, Sheffield, UK. 5Centre for Reproduction Research, School of Applied
Social Science, De Montfort University, Leicester, UK. 6THIS Institute,
University of Cambridge, Cambridge, UK.
Received: 4 October 2019 Accepted: 17 October 2019References
1. Holman N, Young B, Gadsby R. Current prevalence of type 1 and type 2
diabetes in adults and children in the UK. Diabet Med. 2015;32(9):1119–20.
2. Diabetes UK. Diabetes Prevalence 2018. 2018. https://www.diabetes.org.uk/
professionals/position-statements-reports/statistics/diabetes-prevalence-201
8. Accessed 21 Mar 2019.
3. IDF: Diabetes Atlas Eighth Edition. 2017. http://www.diabetesatlas.org/.
4. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and
future costs of type 1 and type 2 diabetes in the UK, including direct health
costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):
855–62.
5. Steinsbekk A, Rygg L, Lisulo M, Rise MB, Fretheim A. Group based diabetes
self-management education compared to routine treatment for people
with type 2 diabetes mellitus. A systematic review with meta-analysis. BMC
Health Serv Res. 2012;12(1):213.
6. Davies M, Heller S, Skinner TC, Campbell M, Carey M, Cradock S, Dallosso H,
Daly H, Doherty Y, Eaton S, et al. Effectiveness of the diabetes education
and self management for ongoing and newly diagnosed (DESMOND)
programme for people with newly diagnosed type 2 diabetes: cluster
randomised controlled trial. Br Med J. 2008;336:491–5.
7. Gillett M, Dallosso HM, Dixon S, Brennan A, Carey ME, Campbell MJ, et al.
Delivering the diabetes education and self management for ongoing and
newly diagnosed (DESMOND) programme for people with newly diagnosed
type 2 diabetes: cost effectiveness analysis. BMJ. 2010;341:c4093.
8. Deakin T, Cade J, Williams R, Greenwood D. Structured patient education:
the Diabetes X-PERT Programme makes a difference. Diabet Med. 2006;
23(9):944–54.
9. Sturt J, Hearnshaw H, Farmer A, Dale J, Eldridge S. The Diabetes manual trial
protocol–a cluster randomized controlled trial of a self-management
intervention for type 2 diabetes [ISRCTN06315411]. BMC Fam Pract. 2006;
7(1):45.
10. Sturt J, Taylor H, Docherty A, Dale J, Louise T. A psychological approach to
providing self-management education for people with type 2 diabetes: the
Diabetes manual. BMC Fam Pract. 2006;7(1):70.
11. Sturt J, Whitlock S, Fox C, Hearnshaw H, Farmer A, Wakelin M, Eldridge S,
Griffiths F, Dale J. Effects of the Diabetes manual 1: 1 structured education
in primary care. Diabet Med. 2008;25(6):722–31.
12. Trento M, Gamba S, Gentile L, Grassi G, Miselli V, Morone G, Passera P,
Tonutti L, Tomalino M, Bondonio P. Rethink organization to iMprove
education and outcomes (ROMEO): a multicenter randomized trial of
lifestyle intervention by group care to manage type 2 diabetes. Diabetes
Care. 2010;33(4):745–7.
13. Chatterjee S, Davies MJ, Heller S, Speight J, Snoek FJ, Khunti K. Diabetes
structured self-management education programmes: a narrative review and
current innovations. Lancet Diabetes Endocrinol. 2018;6(2):130–42.
Davies et al. BMC Family Practice          (2019) 20:152 Page 15 of 1514. Pillay J, Armstrong MJ, Butalia S, Donovan LE, Sigal RJ, Vandermeer B,
Chordiya P, Dhakal S, Hartling L, Nuspl M. Behavioral programs for type 2
diabetes mellitus: a systematic review and network meta-analysis. Ann
Intern Med. 2015;163(11):848–60.
15. He X, Li J, Wang B, Yao Q, Li L, Song R, Shi X, Zhang J-A. Diabetes self-
management education reduces risk of all-cause mortality in type 2
diabetes patients: a systematic review and meta-analysis. Endocrine. 2017;
55:712. https://doi.org/10.1007/s12020-016-1168-2.
16. National Institute for Health and Care Excellence. Guidance on the use of
patient-education models for diabetes. Technology appraisal guidance
[TA60] 2003. Updated August 2015. 2015. https://www.nice.org.uk/
guidance/ta60. Accessed 21 Mar 2019.
17. National Institute for Health and Care Excellence: NICE Quality and
Outcomes Framework indicator. 2016. 2016.
18. NHS Digital: National Diabetes Audit, 2017–18: Care Processes and
Treatment Targets short report. 2018. 2018.
19. All-Party Parliamentary Group for Diabetes. Taking control: supporting
people to self-manage their diabetes. Diabetes UK; 2015. https://diabetes-
resources-production.s3-eu-west-1.amazonaws.com/diabetes-storage/
migration/pdf/APPG%2520Diabetes%2520Report_FINAL.pdf. Accessed 29
Oct 2019.
20. Horigan G, Davies M, Findlay-White F, Chaney D, Coates V. Reasons why
patients referred to diabetes education programmes choose not to attend:
a systematic review. Diabet Med. 2017;34(1):14–26.
21. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M.
Developing and evaluating complex interventions: the new Medical
Research Council guidance. BMJ. 2008;337:a1655.
22. Bryman A. Social research methods. Oxford: Oxford University Press; 2016.
23. Teddlie C, Yu F. Mixed methods sampling: a typology with examples. J
Mixed Methods Res. 2007;1(1):77–100.
24. Holt TA, Fitzmaurice DA, Marshall T, Fay M, Qureshi N, Dalton AR, Hobbs FR,
Lasserson DS, Kearley K, Hislop J. AUtomated risk assessment for stroke in
atrial fibrillation (AURAS-AF)-an automated software system to promote
anticoagulation and reduce stroke risk: study protocol for a cluster
randomised controlled trial. Trials. 2013;14(1):385.
25. Wolfinger NH. On writing fieldnotes: collection strategies and background
expectancies. Qual Res. 2002;2(1):85–93.
26. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework
method for the analysis of qualitative data in multi-disciplinary health
research. BMC Med Res Methodol. 2013;13(1):117.
27. May C. A rational model for assessing and evaluating complex interventions
in health care. BMC Health Serv Res. 2006;6(1):86.
28. Murray E, Treweek S, Pope C, MacFarlane A, Ballini L, Dowrick C, Finch T,
Kennedy A, Mair F, O'Donnell C. Normalisation process theory: a framework
for developing, evaluating and implementing complex interventions. BMC
Med. 2010;8(1):63.
29. Benning A, Ghaleb M, Suokas A, Dixon-Woods M, Dawson J, Barber N,
Franklin BD, Girling A, Hemming K, Carmalt M. Large scale organisational
intervention to improve patient safety in four UK hospitals: mixed method
evaluation. Bmj. 2011;342:d195.
30. Walker S, Mason AR, Claxton K, Cookson R, Fenwick E, Fleetcroft R, Sculpher
M. Value for money and the quality and outcomes framework in primary
care in the UK NHS. Br J Gen Pract. 2010;60(574):e213–20.
31. Gillett M, Brennan A, Watson P, Khunti K, Davies M, Mostafa S, Gray LJ. The
cost-effectiveness of testing strategies for type 2 diabetes: a modelling
study; 2015.
32. Gillett M, Chilcott J, Goyder E, Payne N, Thokala P, Freeman C. Prevention of
Type 2 Diabetes: Risk Identification and Interventions for Individuals at High
Risk – Economic Review and Modelling: ScHARR Public Health Collaborating
Centre; 2012. Available via this link https://www.nice.org.uk/guidance/ph38/
evidence/he1-costeffectiveness-review-and-economic-modelling-435125485
33. Strong M, Oakley JE, Brennan A. Estimating multiparameter partial expected
value of perfect information from a probabilistic sensitivity analysis sample:
a nonparametric regression approach. Med Decis Mak. 2014;34(3):311–26.
34. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D,
Augustovski F, Briggs AH, Mauskopf J, Loder E. Consolidated health
economic evaluation reporting standards (CHEERS) statement. Cost
Effectiveness Resour Allocation. 2013;11(1):6.
35. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up
of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):
1577–89.36. Kristunas CA, Smith KL, Gray LJ. An imbalance in cluster sizes does not lead
to notable loss of power in cross-sectional, stepped-wedge cluster
randomised trials with a continuous outcome. Trials. 2017;18(1):109.
37. Finer S, Robb P, Cowan K, Daly A, Robertson E, Farmer A. Top ten research
priorities for type 2 diabetes: results from the Diabetes UK–James Lind
Alliance priority setting partnership. Lancet Diabetes Endocrinol. 2017;5(12):
935–6.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
